CStone Management Boosts Shareholdings as Key Immuno-Oncology Asset AdvancesTip Ranks·Jul 22 at 05:37 PM02616+3.10%
CStone’s Trispecific Cancer Antibody CS2009 Secures Dual Rapid Oral Slots at ESMO 2026Tip Ranks·Jul 19 at 07:07 PM02616+3.10%
Zhihu files HKEX next-day disclosure return reporting share repurchase for cancellationPUBT·Jun 26 at 04:05 AM02390-1.29%ZH-0.30%
CStone signs exclusive sugemalimab commercialization deal with Arrotex for Australia, New ZealandPUBT·Jun 25 at 04:01 AM02616+3.10%
CStone files HKEX next-day disclosure return on share repurchase for cancellationPUBT·Jun 24 at 09:30 AM02616+3.10%
CStone Shareholders Approve All AGM Resolutions, Renew Capital Mandates and CEO Equity AwardsTip Ranks·Jun 23 at 06:13 PM02616+3.10%
CStone Pharmaceuticals files HKEX next-day disclosure, reports share repurchase for cancellationPUBT·Jun 22 at 06:39 AM02616+3.10%
Kanzhun files HKEX next-day disclosure return reporting share repurchase for cancellationPUBT·Jun 18 at 05:01 AMBZ-0.73%02076-1.56%
CStone files HKEX next-day return disclosing share repurchase for cancellation at HKD 4.53-4.83PUBT·Jun 17 at 05:33 AM02616+3.10%
CStone Launches Global Phase I Trial for New EGFR/HER3 Bispecific ADCTip Ranks·Jun 11 at 06:05 PM02616+3.10%
